Welcome to our dedicated page for VIEMED HEALTHCARE SEC filings (Ticker: VMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Viemed Healthcare, Inc. filings document the public-company reporting of a British Columbia issuer with Nasdaq-listed common shares and a U.S. home-based healthcare business. Recent Form 8-K reports furnish quarterly and annual financial results, financial supplements, guidance updates, investor presentation materials, and Regulation FD disclosures tied to Viemed's home medical equipment and chronic disease management operations.
The filing record also covers capital and governance matters, including a definitive proxy statement with annual meeting, governance, and executive compensation disclosures; credit agreement amendments involving Viemed subsidiaries and lenders; and common-share repurchase authorizations and completed repurchase activity. These filings describe the company's capital structure, material agreements, board actions, and formal disclosure controls around furnished operating updates.
Viemed Healthcare, Inc. reported Q2 2026 revenue of 78,097 thousand USD, up 23.9% from 63,056 thousand a year earlier, driven by growth in ventilator rentals, other home medical equipment, and equipment and supply sales, including contributions from the Lehan Drugs acquisition.
Gross profit rose to 45,048 thousand USD, but income from operations slipped to 4,461 thousand and net income attributable to Viemed decreased to 2,764 thousand, with diluted EPS of 0.07 versus 0.08. Adjusted EBITDA was 13,715 thousand, as higher selling, general and administrative costs and losses on asset disposals weighed on margins.
For the first six months of 2026, net cash provided by operating activities increased to 23,973 thousand USD, funding 15,172 thousand of capital expenditures and continued debt reduction. Debt under the 2022 Senior Credit Facilities declined to 7,445 thousand, cash ended at 10,680 thousand, and total assets reached 204,224 thousand.
Viemed Healthcare reported record second-quarter 2026 net revenue of $78.1 million, up 23.9% from a year earlier and 3.6% sequentially. Net income attributable to the company was $2.8 million, or $0.07 per diluted share, while Adjusted EBITDA was $13.7 million, a 4.0% year-over-year decrease. The company generated $15.9 million of operating cash flow and $8.6 million of free cash flow in the quarter.
Viemed ended June 30, 2026 with $10.7 million in cash, long-term debt of $6.4 million, working capital of $6.1 million, and $46 million available under existing credit facilities. The company reported a record 12,635 ventilator patients, plus strong growth in PAP therapy and sleep resupply patients, and repurchased 530,802 shares for $5.1 million. Full-year 2026 net revenue guidance was raised to $314–$320 million, Adjusted EBITDA guidance set at $64–$68 million, and net capital expenditures are now expected at 8.5%–10.0% of net revenue.
Viemed Healthcare, Inc. is the subject of an amended Schedule 13G filing by Forager Fund, L.P., Forager Capital Management, LLC, and individuals Edward Kissel and Robert MacArthur. The reporting group states that, in the aggregate, they beneficially own 1,886,872 shares of Viemed common stock.
This position represents 4.9% of the 38,336,802 shares of common stock outstanding as of April 29, 2026, as reported in Viemed’s Form 10-Q for the quarter ended March 31, 2026. Forager Fund and its general partner each have sole voting and dispositive power over these shares, while Messrs. Kissel and MacArthur report shared voting and dispositive power over the same 1,886,872 shares, reflecting their roles in managing the fund. The filing notes that the group’s holdings are at or below the 5 percent ownership threshold.
Viemed Healthcare Chief Medical Officer William Frazier reported an exercise-and-sell transaction in Viemed Healthcare, Inc. common shares. He exercised stock options for 10,000 Common Shares at $1.81 per share, then sold 10,000 Common Shares in an open-market sale at $11.72 per share on the same date.
After these transactions, Frazier directly holds 73,214 Common Shares and retains 26,261 Stock Options, which are fully vested and expire on January 4, 2028. The filing shows a net reduction of 10,000 common shares in his direct holdings.
VIEMED HEALTHCARE, INC. director Timothy Smokoff reported open-market sales of a total of 20,000 Common Shares of VMD on June 24, 2026. The transactions were executed in five separate trades at prices ranging from $11.41 to $11.56 per share.
Viemed Healthcare, Inc. reported the results of its Annual General and Special Meeting. Shareholders approved a second amendment to the 2024 Long Term Incentive Plan, increasing the maximum number of common shares reserved for issuance under current and prior equity plans to 7,696,717, including up to 1,000,000 incentive stock options. All seven director nominees were elected, each receiving at least 79.76% support, with broker non-votes of 5,139,303 on the election item. Shareholders also approved the appointment of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026. The equity plan amendment and executive compensation received strong backing, with 88.85% and 93.21% of votes cast in favor, respectively, on the compensation-related resolutions.
Viemed Healthcare highlights strong growth and guidance in its June 2026 investor presentation. Net revenue reached $270 million in 2025, up 28% year over year, with Adjusted EBITDA of $61 million and free cash flow of $28 million, all with no net debt. The company reports a 26% compounded annual revenue growth rate since listing, serves over 183,000 patients across all 50 states, and has diversified beyond ventilation into sleep, oxygen, airway clearance, women’s health and staffing. For 2026, Viemed guides to net revenue of $312–$320 million and Adjusted EBITDA of $65–$69 million, while maintaining net capex at 9–10.5% of revenue and trailing twelve-month free cash flow of about $36 million. Management is also executing a new share repurchase program of up to 5% of shares outstanding, supported by cash generation and $46 million of credit facility availability.
Viemed Healthcare, Inc. reported strong top-line growth for the quarter ended March 31, 2026. Revenue rose to $75.4 million from $59.1 million, driven by broader rental activity and a sharp increase in equipment and supply sales.
Ventilator rentals generated $35.4 million and other home medical equipment rentals $16.2 million, while equipment and supply sales more than doubled to $17.5 million, aided by women’s health products and the Lehan Drugs acquisition. Gross margin was 56.8%, slightly above last year.
Net income attributable to Viemed was $2.6 million, essentially flat year over year, with diluted EPS of $0.06. Operating cash flow improved to $8.1 million, supporting $6.7 million of capital spending and $3.2 million of debt repayment. Cash ended at $9.8 million and total debt at $9.6 million, with shareholders’ equity of $145.8 million.
Viemed Healthcare reported strong first quarter 2026 growth while narrowing and raising its full-year outlook. Net revenue for the quarter ended March 31, 2026 was $75.4 million, up 28% from the prior-year quarter. Net income attributable to Viemed was $2.6 million, or $0.06 per diluted share, and Adjusted EBITDA rose 12% to $14.3 million, despite a non-recurring gain in the prior year.
The company generated $8.1 million of operating cash flow and $2.6 million of free cash flow in the quarter, repurchased 150,000 shares for $1.4 million, and reduced term debt by $3.2 million. Management now expects 2026 net revenue of $312–$320 million, Adjusted EBITDA of $65–$69 million, and lower net capital intensity of 9%–10.5% of net revenue.
Viemed Healthcare, Inc. is calling a 2026 annual general and special meeting to elect seven directors, ratify Ernst & Young LLP as auditor, amend its 2024 Long Term Incentive Plan, and hold a non-binding say‑on‑pay vote.
The equity plan amendment would lift the combined share reserve under current and prior equity plans to 7,696,717 common shares, or 20% of the 38,483,586 shares outstanding as of April 8, 2026. Directors and executive officers together beneficially own 7,912,538 shares, or 20.6% of outstanding shares, while BlackRock, Inc. and Forager Fund, L.P. hold 6.6% and 7.1%, respectively.